Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psoriasis

Ron Menezes joins Almirall’s Aqua Pharmaceuticals

He joins the US dermatology group as its president and general manager

- PMLiVE

European Commission backs LEO Pharma’s Kyntheum

Drug has been approved to treat moderate-to-severe plaque psoriasis

- PMLiVE

J&J aiming for above-average growth thanks to stream of blockbusters

US firm enters highly productive R&D phase

- PMLiVE

ThermiGen appoints Vladimir Paul-Blanc as president

He will also serve as the Almirall-owned firm's general manager

What next for the treatment of Psoriasis in Europe?

Research Director Laurent Chanroux investigates the changing market dynamics in Psoriasis in Europe.

Research Partnership

- PMLiVE

Almirall launches story campaign to raise rosacea awareness

The Red Girl highlights the negative psychological effects of the disease

Novartis day

Could Cosentyx free psoriasis patients from treatment?

One in five patients on the Novartis treatment remained symptom-free for a year

- PMLiVE

FDA OKs Valeant’s psoriasis drug Siliq, with black box warning

Suicidal ideation labelling adds to challenge in rivalling Novartis’ Cosentyx and Lilly’s Taltz

Novartis building

Novartis adds oral eczema drug with Ziarco acquisition

Expands dermatology pipeline with first-in-class, Pfizer-developed treatment prospect

- PMLiVE

Janssen files Stelara follow-up guselkumab in Europe

Trial data shows J&J’s drug is more effective in treating psoriasis than AbbVie’s Humira

- PMLiVE

Biogen launches Remicade biosimilar in the UK

Flixabi provides another low-cost alternative to J&J’s biggest-selling drug

Novartis day

Novartis claims first place for its biosimilar Enbrel in US

However, Amgen’s patent infringement lawsuit could delay the launch of Erelzi

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links